在我国,胰腺是神经内分泌肿瘤最为常见的发生部位。胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,简称pNETs)是一类起源于胰腺多能神经内分泌干细胞的肿瘤,在所有胰腺肿瘤中所占的比例大约为1%~2%。随着公众健康意识的日益增长以及检测技术的不断进步,pNETs的发病率和检出率都在逐年升高,但针对pNETs的治疗目前仍以手术治疗为主要手段,并且根治性手术切除被公认为唯一可能彻底治愈pNETs的方法;但令人痛惜的是,很多患者在确诊时已进展至中晚期,已错过了行根治性手术的机会;幸运的是,目前结合其他化疗、放疗、免疫等非手术治疗,疗效也大幅提升。但提高对该病的认识,进行科学的“排兵布阵”,实行精准的个体化治疗,才更有利于提高该疾病的生存期。为了更精准地制定个体化治疗方案,本文就近年来胰腺神经内分泌肿瘤的治疗进展做一概述。In China, the pancreas is the most common site of neuroendocrine tumors. Pancreatic neuroendocrine tumors (PNETs) are a class of tumors originating from pancreatic pluripotent neuroendocrine stem cells, accounting for about 1% to 2% of all pancreatic tumors. With the growing awareness of public health and the continuous progress of detection technology, the incidence and detection rates of PNETs are increasing year by year. However, surgical treatment is still the main treatment for PNETs, and radical surgical resection is recognized as the only method that can completely cure PNETs;However, it is regrettable that many patients have progressed to the middle and late stage at the time of diagnosis, and have missed the opportunity of radical surgery. Fortunately, the curative effect has also been greatly improved in combination with other non-surgical treatments such as chemotherapy, radiotherapy and immunization. However, to improve the understanding of the disease, carry out scientific “troop arrangement”, and implement accurate and indiv
垂体神经内分泌肿瘤是一种常见的颅内肿瘤,治疗方式主要为经蝶或经颅垂体瘤切除术,对于手术治疗的患者,术后是否复发会影响患者后续治疗方案以及生存预后,其中侵入鞍上或鞍旁区域的PitNET由于术中难以完全切除,术后12%~58%的患者会出现复发(本文复发定义采用2019年中国复发性垂体腺瘤诊治专家共识中的定义:垂体腺瘤切除术后已消失的症状体征再次出现;内分泌指标达到缓解标准后再次升高;影像学检查再次出现肿瘤生长),即使瘤体被完全切除,10%~20%仍会在5~10年内复发。肿瘤的复发给患者带来经济和心理负担的同时降低了其生活质量。本文主要从影像学特征、病理学因素及其他因素三方面对术后PitNET复发的因素进行综述,以及对临床中PitNET的治疗方式提出个人建议,旨在为该病的临床治疗提供参考。Pituitary neuroendocrine tumor is a common intracranial tumor, and the treatment is mainly transsphenoidal or transcranial pituitary tumor resection. For patients undergoing surgical treatment, whether postoperative recurrence will affect the follow-up treatment plan and survival prognosis of the patients. Among them, the PitNET that invaded the suprasellar or parasellar area was difficult to be completely removed during surgery, and recurred in 12%~58% of patients after surgery. (In this paper, the definition of relapse was adopted in the expert consensus on diagnosis and treatment of recurrent pituitary adenoma in China in 2019: symptoms and signs that had disappeared after pituitary adenoma resection reappeared;Endocrine indexes increased again after reaching the remission standard;Tumor growth reappears on imaging.) And even if the tumor is completely removed, 10%~20% will recur within 5 to 10 years. The recurrence of tumors brings financial and psychological burden to patients and reduces their quality of life. This article mainly reviews the factors of postoperative recurrence of PitNET from thr
